Novozymes A/S
Novozymes A/S Fundamental Analysis
Novozymes A/S (NVZMF) shows strong financial fundamentals with a PE ratio of 10.28, profit margin of 13.43%, and ROE of 21.92%. The company generates $17.6B in annual revenue with moderate year-over-year growth of 8.46%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 66.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze NVZMF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNVZMF demonstrates superior asset utilization.
Valuation Score
ExcellentNVZMF trades at attractive valuation levels.
Growth Score
ExcellentNVZMF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentNVZMF maintains a strong and stable balance sheet.
Profitability Score
ModerateNVZMF maintains healthy but balanced margins.
Key Financial Metrics
Is NVZMF Expensive or Cheap?
P/E Ratio
NVZMF trades at 10.28 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NVZMF's PEG of -0.34 indicates potential undervaluation.
Price to Book
The market values Novozymes A/S at 2.23 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.69 times EBITDA. This is generally considered low.
How Well Does NVZMF Make Money?
Net Profit Margin
For every $100 in sales, Novozymes A/S keeps $13.43 as profit after all expenses.
Operating Margin
Core operations generate 18.99 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $21.92 in profit for every $100 of shareholder equity.
ROA
Novozymes A/S generates $14.33 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Novozymes A/S generates limited operating cash flow of $1.28B, signaling weaker underlying cash strength.
Free Cash Flow
Novozymes A/S produces free cash flow of $784.54M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.68 in free cash annually.
FCF Yield
NVZMF converts 3.22% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
10.28
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.34
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.23
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.38
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.29
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.67
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.22
vs 25 benchmark
ROA
Return on assets percentage
0.14
vs 25 benchmark
ROCE
Return on capital employed
0.22
vs 25 benchmark
How NVZMF Stacks Against Its Sector Peers
| Metric | NVZMF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 10.28 | 25.21 | Better (Cheaper) |
| ROE | 21.92% | 937.00% | Weak |
| Net Margin | 13.43% | -104848.00% (disorted) | Strong |
| Debt/Equity | 0.29 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 1.67 | 6.85 | Neutral |
| ROA | 14.33% | -2767.00% (disorted) | Strong |
NVZMF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Novozymes A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-79.94%
Industry Style: Cyclical, Commodity, Value
DecliningEPS CAGR
-86.04%
Industry Style: Cyclical, Commodity, Value
DecliningFCF CAGR
-81.03%
Industry Style: Cyclical, Commodity, Value
Declining